Suppr超能文献

中性粒细胞与淋巴细胞比值可预测非小细胞肺癌术后复发患者的生存情况

[Neutrophil-to-lymphocyte ratio predicts the survival in patients with post-operative recurrence of non-small cell lung cancer].

作者信息

Wang Xinyue, Li Kai

机构信息

Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Treatment of Tianjin City, Tianjin 300060, China.

Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Treatment of Tianjin City, Tianjin 300060, China. Email:

出版信息

Zhonghua Zhong Liu Za Zhi. 2014 Apr;36(4):298-302.

Abstract

OBJECTIVE

To analyze the impact of neutrophil-to-lymphocyte ratio (NLR) on survival of patients with post-operative recurrence of non-small cell lung cancer (NSCLC).

METHODS

The clinicopathological characteristics and outcome data of 235 patients with post-operative recurrent NSCLC were collected and reviewed. The best cut-off value of NLR at recurrence was identified according to the receiver operating characteristic curve (ROC curve), and all 235 patients were therefore divided into two groups based on the NLR value. The prognostic impact of NLR on survival in patients with recurrent NSCLC was tested by univariate and multivariate analyses.

RESULTS

The NLR of 2.97 was identified as the optimal cut-off value. There was no statistically significant difference in the clinicopathological characteristics between the low NLR (NLR ≤ 2.97) and high NLR (NLR>2.97) groups at recurrence. The median post-recurrence survival of 235 patients was 13 months (range, 1-81 months). The post-recurrence 1-, 2-year survival rates were 58.4% and 32.6%, respectively. Univariate analysis showed that age at the time of operation >65 years (P = 0.009), a histological type of large cell lung cancer or sarcoma (P < 0.001), TNM stage III of the primary tumor (P = 0.043) and NLR>2.97 at recurrence (P < 0.001) were prognostic risk factors for post-recurrence survival, while preoperative NLR>2.97 was not (P = 0.104). The post-recurrence 1- and 2-year survival rates of the low recurrence NLR group were 74.7% and 43.1%, respectively, significantly higher than that of the high recurrence NLR group (35.4% and 17.2%, respectively) (P < 0.001). Cox multivariate analysis showed that age >65 (HR = 1.707, P = 0.001), TNM stage III of primary tumor (HR = 1.654, P = 0.001) and NLR>2.97 (HR = 2.859, P < 0.001) at recurrence were independent prognostic factors (P < 0.05 for all).

CONCLUSIONS

An elevated NLR at recurrence indicates poor prognosis of NSCLC patients. NLR at recurrence may be an important independent prognostic factor of patients with recurrent NSCLC after curative resection.

摘要

目的

分析中性粒细胞与淋巴细胞比值(NLR)对非小细胞肺癌(NSCLC)术后复发患者生存的影响。

方法

收集并回顾235例NSCLC术后复发患者的临床病理特征及预后数据。根据受试者工作特征曲线(ROC曲线)确定复发时NLR的最佳截断值,因此将所有235例患者根据NLR值分为两组。通过单因素和多因素分析检测NLR对复发NSCLC患者生存的预后影响。

结果

确定2.97为最佳截断值。复发时低NLR组(NLR≤2.97)和高NLR组(NLR>2.97)的临床病理特征无统计学显著差异。235例患者复发后的中位生存期为13个月(范围1 - 81个月)。复发后1年、2年生存率分别为58.4%和32.6%。单因素分析显示,手术时年龄>65岁(P = 0.009)、组织学类型为大细胞肺癌或肉瘤(P < 0.001)、原发肿瘤TNM分期为III期(P = 0.043)以及复发时NLR>2.97(P < 0.001)是复发后生存的预后危险因素,而术前NLR>2.97不是(P = 0.104)。低复发NLR组复发后1年和2年生存率分别为74.7%和43.1%,显著高于高复发NLR组(分别为35.4%和17.2%)(P < 0.001)。Cox多因素分析显示,复发时年龄>65岁(HR = 1.707,P = 0.001)、原发肿瘤TNM分期为III期(HR = 1.654,P = 0.001)和NLR>2.97(HR = 2.859,P < 0.001)是独立预后因素(均P < 0.05)。

结论

复发时NLR升高提示NSCLC患者预后不良。复发时NLR可能是根治性切除术后复发NSCLC患者的重要独立预后因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验